纳林: Roxadustat 在慢性病相关贫血与腹腔透析中的有效性/安全性
Zhiming Ye1, Gang Xu2, Hao Zhang3
1Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, PR China.
Kidney diseases (Basel, Switzerland)
|January 8, 2026
概括
在接受腹腔透析 (PD) 的中国患者中,口服罗沙沙沙特有效治疗贫血,改善了他们的生活质量. 该疗法显示出与已知的特征相一致的有利安全概况.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 口腔贫血的治疗方法更喜欢在家里进行腹膜透析 (PD) 的患者.
- 慢性病 (CKD) 相关的贫血是PD患者常见的并发症.
- 评估PD贫血管理的新型口服药物至关重要.
研究的目的:
- 评估口服罗沙沙斯塔特治疗中国CKD/PD患者贫血的有效性和安全性.
- 评估roxadustat对该患者群体生活质量的影响.
- 根据2型糖尿病 (T2DM) 状态对有效性进行分层.
主要方法:
- 第4期研究涉及195名患有CKD相关的PD贫血的中国患者.
- 患者在24周内每周服用三次口服罗沙杜沙特.
- 评估血红蛋白水平,生活质量 (FACT-An,SF-36) 和安全性,包括治疗出现的不良事件.
主要成果:
- 85.1%的患者达到血红蛋白≥100g/L,包括89.2%的T2DM和84.0%没有T2DM.
- 观察到生活质量的临床显著改善 (FACT-An得分变化: -6.2).
- 治疗引起的不良事件发生在81.0%的患者中,其中10.3%与roxadustat有关.
结论:
- 口服罗沙沙斯塔特有效地纠正了中国患者的贫血 CKD 在PD,无论T2DM状态.
- 副作用与roxadustat已知的安全性和PD患者特征一致.
- 罗沙杜沙特 (Roxadustat) 是一种可行的口服治疗方案,用于PD患者的贫血.
相关概念视频
01:28Chronic Kidney Disease III: Interprofessional Care
333
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
333
01:25Peritoneal Dialysis III: Nursing Management
644
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
644
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
513
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
513
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
205
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
205
01:24Chronic Kidney Disease II: Clinical Manifestations
543
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
543
01:11Renal Failure: Dose Adjustments
429
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
429